Endometrial Preparation With Estradiol Plus Dienogest (Qlaira) for Office Hysteroscopic Polypectomy: Randomized Pilot Study

Cicinelli, Ettore; Pinto, Vincenzo; Quattromini, P.; Fucci, Maria Rosa; Lepera, Achiropita; Mitola, Paola Carmela; Cicinelli, Maria Vittoria; Fusco, Alfredo; Tinelli, Raffaele

doi:10.1016/j.jmig.2011.12.020

Cited by 23 publications

(15 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twelve patients in each group had both thinned and clearly visualized endometrium during surgery [11]. Similar to this study, Cicinelli et al [12] showed thinner and well-prepared endometrium before hysteroscopic polypectomy was performed in patients who were administered estradiol plus DIE. In both studies, they emphasized that DIE is a specific progesterone receptor agonist with a strong antiproliferative effect on endometrial activity with higher patient compliance and low risks.…”

Section: Discussionsupporting

confidence: 82%

“…It is already known that progestins accelerate signaling pathways that inhibit the transformation of endometrial cells to cancer progression [12]. However, there is a debate as to which progestin type is better.…”

Section: Discussionmentioning

confidence: 99%

“…They showed that the administration of DIE (2 mg orally in a day) for 2 weeks thinned the endometrium. Moreover, Cicinelli et al [12] showed that those in the group that was administrated estradiol plus DIE before hysteroscopy procedure had thinner endometrial thickness compared to those who were not administered the drug. Therefore, we hypothesized that DIE may be used in the treatment of EH.…”

mentioning

confidence: 99%

See 2 more Smart Citations

The Efficacy of Dienogest in the Treatment of Simple Endometrial Hyperplasia without Atypia

Uysal

Açmaz²,

Madendağ³

et al. 2017

Gynecol Obstet Invest

View full text Add to dashboard Cite

Aim: The aim of the study was to compare the effectiveness of dienogest (DIE), depo medroxyprogesterone 17-acetate (MPA), and micronized progesteron (MP) regimens for treatment of simple endometrial hyperplasia (EH) without atypia. Methods: One hundred and twenty premenopausal patients aged between 35 and 55, with simple EH without atypia, were offered 3 types of progestins (MPA, MP, and DIE) and were randomized to one of them. After 6 months of treatment, patients were reevaluated. The efficacy of different progestins in treatment of EH was compared with regard to resolution and regression rates. We classified the terms of resolution and regression as “complete response” and persistence as “no response”. Results: A total of 99 patients continued the study (31 in MP, 35 in MPA, and 33 in the DIE group). None of the results of endometrial pathology were progressed to atypia or complex hyperplasia. The complete response resolution rate was 93.5% in the MP, 88.5% in the MPA, and 96.9% in the DIE group. The highest complete response rate was in the DIE group, although there was no statistically significant difference between groups (p = 0.39). The efficacy of progestins was similar between the groups. Conclusion: DIE is an effective and convenient method for thinning the endometrium.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

The Efficacy of Dienogest in the Treatment of Simple Endometrial Hyperplasia without Atypia

Uysal

Açmaz²,

Madendağ³

et al. 2017

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…From the initial electronic search, 16 original research articles reporting the E 2 V/DNG oral contraceptive were identified based on abstract/title information and retrieved;11,13,15–28 the full articles were assessed, and eight articles that reported noncontraceptive benefits of E 2 V/DNG (loosely defined as any perceived benefit beyond safety and contraceptive efficacy, or related surrogate outcomes) were identified for inclusion 13,15–18,22,24,28. Of the other publications, one was a pooled study summarizing menstrual blood loss (MBL) data across two individual studies previously identified, and was included as appropriate 23.…”

Section: Methodsmentioning

confidence: 99%

“…However, larger, longer-term RCTs that include a comparator are needed to confirm whether E 2 V/DNG offers any advantage over other COC formulations, for the treatment of acne. E 2 V/DNG has also been assessed as a strategy for endometrial preparation prior to operative hysteroscopy, with two small randomized studies supporting that pretreatment with E 2 V/DNG improved the subjective ease of the procedure 22,37. Again, larger RCTs are needed to confirm whether E 2 V/DNG pretreatment offers any advantage over other COC formulations with regard to operative hysteroscopy procedures.…”

Section: Methodsmentioning

confidence: 99%

Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature

Nappi¹,

Serrani²,

Jensen³

2014

IJWH

View full text Add to dashboard Cite

Combined oral contraceptives formulated to include estradiol (E2) have recently become available for the indication of pregnancy prevention. A combined estradiol valerate and dienogest pill (E2V/DNG), designed to be administered using an estrogen step-down and a progestin step-up regimen over 26 days of active treatment followed by 2 days of placebo (26/2-day regimen), has also undergone research to assess the potential for additional noncontraceptive benefits. Randomized, placebo-controlled studies have demonstrated that E2V/DNG is an effective treatment for heavy menstrual bleeding – a reduction in median menstrual blood loss approaching 90% occurs after 6 months of treatment. To date, E2V/DNG is the only oral contraceptive approved for this indication. Comparator studies have also demonstrated a reduction in hormone withdrawal-associated symptoms in users of E2V/DNG compared with a conventional 21/7-day regimen of ethinylestradiol/levonorgestrel. Other potential noncontraceptive benefits associated with E2V/DNG, like improvement in dysmenorrhea, sexual function, and quality of life, are comparable with those associated with other combined oral contraceptives and are discussed further in this review.

show abstract

Endometrial Presurgical Preparation

Tinelli

Cicinelli

2017

Hysteroscopy

View full text Add to dashboard Cite

Endometrial Preparation With Estradiol Plus Dienogest (Qlaira) for Office Hysteroscopic Polypectomy: Randomized Pilot Study

Cited by 23 publications

References 11 publications

The Efficacy of Dienogest in the Treatment of Simple Endometrial Hyperplasia without Atypia

The Efficacy of Dienogest in the Treatment of Simple Endometrial Hyperplasia without Atypia

Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature

Endometrial Presurgical Preparation

Contact Info

Product

Resources

About